Journal of Medicinal Chemistry · 2006 · 91 citations · 29 references
Life SciencesBiochemistryPharmacologyDrug DiscoveryMarine MicrobiologyMarine SymbiosisCnidarian SymbiosesMarine Bioactive CompoundsMarine Drug DiscoveryMarine Microbial MetabolismMarine Natural ProductsPeptide ChemistryCyclic PeptidesMarine Cyanobacterial MetabolitesMarine Secondary MetabolitesMarine Sponge MetabolitesMarine-derived Enzyme InhibitorsSecondary MetabolitesSponges-derived MetabolitesSymbiotic Marine Organisms As Drug Sources
The cyanobacterium Tychonema sp. produces the new cyclic hexapeptides brunsvicamide A-C (1-3). Brunsvicamide B (2) and C (3) selectively inhibit the Mycobacterium tuberculosis protein tyrosine phosphatase B (MptpB), a potential drug target for tuberculosis therapy for which no inhibitors are known to date. Brunsvicamide C contains an N-methylated N'-formylkynurenine moiety, a unique structural motif in cyclic peptides. The new peptides are related to the sponge-derived mozamides, supporting the suggestion that secondary metabolites of certain marine invertebrates are produced by associated microorganisms. Thus, microorganisms phylogenetically related to symbionts of marine invertebrates can be judged as a means to supply "marine-like" compounds for drug development.
29
Bergey's Manual of Systematic Bacteriology
Annals of Internal Medicine · 1990 · 15.7K citations
16S ribosomal DNA amplification for phylogenetic study
W G Weisburg, Susan M. Barns, Dale A. Pelletier et al. · Journal of Bacteriology · 1991 · 11.8K citations · Full text
Bergey's Manual of Systematic Bacteriology
Annals of Internal Medicine · 1989 · 3K citations · Full text